2024 International Congress of Parkinson's Disease and Movement Disorders (MDS Congress)
A Phase 2 study of ATH434, a Novel Inhibitor of α-synuclein Aggregation, for the Treatment of Multiple System Atrophy
Association Between Clinical Progression in Multiple System Atrophy and Brain Volume Changes Evaluated via Deep Learning Segmentation
Effects of ATH434, a Clinical-Phase Small Molecule with Moderate Affinity for Iron, in Hemiparkinsonian Macaques
Share your feedback
Discover